Clinical Trial Update: Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites [Phase 1]

View source ↗

Summary

Phase 1 feasibility study of intraperitoneal bevacizumab for palliation of malignant ascites. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Eastern Regional Medical Center | Conditions: Malignant Ascites | Phase 1 | Status: TERMINATED